LifeArc Ventures Amplifies Investments and Expands Team Efforts
LifeArc Ventures, the investment side of the medical research organization LifeArc, saw tremendous growth as it embraced new strategies and expanded its presence in 2025. This remarkable year included significant investments into four innovative life sciences companies. Their portfolio reached a notable height of 20 companies, reflecting a year filled with proactive funding and support.
Significant Growth with Strategic Investments
Since its inception in 2020, LifeArc Ventures has focused on building a diverse and responsive portfolio. The venture capital firm began with Seed and Series A investments and, notably, transitioned into Series B funding rounds in 2025. Active participation in two high-impact Series B rounds distinguished this year, with LifeArc Ventures collaborating with esteemed global syndicates. The anticipation for 2026 is high, promising even greater progress and multiple clinical launches.
Expanding Geographic Reach
Clare Terlouw, Managing Partner of LifeArc Ventures, highlighted the organization's expansion into new territories. "This year we've announced four new investments including our first in countries like Germany, Switzerland, and Scandinavia. This is part of our strategic drive to diversify while retaining a focus on the UK market. Our investments are evolving positively, and we are excited to attract skilled professionals who can enhance our ambitions," she stated. Looking ahead, LifeArc Ventures expects 2026 to be a remarkable year for both its portfolio companies and the fund itself.
Broad Investment Strategies
LifeArc Ventures is determined to secure broad investments across different therapeutic areas and tech-enabled biotechnologies. This includes funding projects aimed at addressing significant unmet medical needs. Their investment strategy not only focuses on individual companies but also encompasses a fund of funds approach, having invested in ten leading global life sciences venture funds. The objective is to ensure financial sustainability while fostering groundbreaking scientific ideas that can change lives.
Building a Specialized Team
To support its investment strategy, LifeArc Ventures appointed Olivia Cavlan, MD, as Partner, and Diana Röttger as Investment Principal in 2025. This growth adds crucial expertise in commercial, operational, and scientific domains, allowing the organization to source and manage lucrative investments actively while overseeing the existing portfolio's governance and growth.
Strategic High-Impact Investments
The year 2025 showcased several high-stakes investments across varying therapeutic modalities that are geared towards addressing pressing healthcare needs. LifeArc Ventures made substantial strides, deploying capital into numerous innovative technologies:
Highlighting Key Investments
Among the notable investments, LifeArc Ventures participated in:
- GlycoEra AG's $130 million Series B, collaborating with multiple stakeholders to enhance their clinical stage development targeting autoimmune conditions.
- Hillstar Bio's $67 million Series A, aimed at bolstering precision immunotherapy solutions in the U.S.
- Exciva's €51 million Series B, to further develop a treatment for agitation linked to Alzheimer's disease.
- Tribune Therapeutics' €23 million Series A, which aims to revolutionize treatment for idiopathic pulmonary fibrosis.
Supporting Existing Portfolio Companies
LifeArc Ventures also backtracked its focus onto existing portfolio companies by supporting significant funding rounds, including:
- Maxion Therapeutics' $72 million Series A, with plans to advance their flagship product for treating inflammatory diseases to clinical proof-of-concept.
- Affect Therapeutics' $26 million Series B, integrating behavioral therapy and biological monitoring to tackle substance use disorders on a larger scale.
Substantial Achievements in Portfolio Development
As 2025 unfolded, many of LifeArc Ventures’ portfolio companies achieved monumental success in their respective fields, with advancements that included:
- AviadoBio and UgeneX Therapeutics forming an exclusive license agreement for a groundbreaking optogenetics gene therapy.
- Fluid Biomed advancing in leadership to optimize its development of a pioneering stent for treating brain aneurysms.
- Ikarovec receiving promising FDA feedback for its gene therapy, which shows potential in treating geographic atrophy.
- Maxion Therapeutics increasing its executive expertise to drive innovative development.
- RQ Bio making strides in seasonal influenza solutions, building on previous COVID-19 success.
About LifeArc
LifeArc is more than just a medical research organization; it stands as a dedicated entity committed to transforming the lives of those facing rare diseases and drug-resistant infections. The organization emphasizes revolutionary research and collaborations that translate scientific breakthroughs into effective solutions for patients. LifeArc Ventures plays a crucial role by funding promising life sciences companies, ensuring impactful advances in healthcare.
Frequently Asked Questions
What is LifeArc Ventures?
LifeArc Ventures is the venture capital arm of LifeArc, focused on investing in innovative life sciences companies.
What achievements did LifeArc Ventures make in 2025?
In 2025, LifeArc Ventures made notable investments into four new companies and supported a range of existing firms across various therapeutic areas.
Who are the key individuals at LifeArc Ventures?
Clare Terlouw serves as the Managing Partner, along with Olivia Cavlan and Diana Röttger, who have recently joined the team.
What is the vision of LifeArc?
LifeArc aims to transform lives by advancing research, funding innovations, and ensuring that scientific breakthroughs reach patients effectively.
How does LifeArc Ventures support its investments?
LifeArc Ventures not only invests capital but also offers management support and governance to ensure the growth and sustainability of its portfolio companies.
